Minerva Neurosciences logo

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
Management to host conference call WALTHAM, Mass. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
Management to host conference call WALTHAM, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
Management to host conference call WALTHAM, Mass. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016 View HTML
Toggle Summary Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015 View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
Management to host conference call WALTHAM, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
Management to host conference call WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
Management to host conference call WALTHAM, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
Management to host conference call WALTHAM, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
WALTHAM, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business
View HTML
Displaying 11 - 20 of 195 results